12.42
0.49 (4.11%)
| Previous Close | 11.93 |
| Open | 11.74 |
| Volume | 3,915,301 |
| Avg. Volume (3M) | 6,466,135 |
| Market Cap | 2,508,165,632 |
| Price / Sales | 26.90 |
| Price / Book | 16.87 |
| 52 Weeks Range | |
| Earnings Date | 11 Nov 2026 |
| Diluted EPS (TTM) | -0.360 |
| Total Debt/Equity (MRQ) | 3.13% |
| Current Ratio (MRQ) | 4.64 |
| Operating Cash Flow (TTM) | -33.71 M |
| Levered Free Cash Flow (TTM) | -23.98 M |
| Return on Assets (TTM) | -58.79% |
| Return on Equity (TTM) | -144.90% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | SELLAS Life Sciences Group, Inc | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.0 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | -1.67 |
Select this tab to load the latest available analysis.
|
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.34% |
| % Held by Institutions | 14.34% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Anson Funds Management Lp | 30 Jun 2026 | 4,500,000 |
| Dagco, Inc. | 30 Jun 2026 | 1,232,433 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |